ASME Hosts Congressional Briefing Focusing on the Future of Regenerative Medicine


May 10, 2019


Dean Kamen, executive director of the Advanced Regenerative Manufacturing Institute, discussed the institute’s new tissue foundry during the keynote address at the congressional briefing on April 10.

ASME recently sponsored a briefing on Capitol Hill in partnership with the House Manufacturing Caucus to highlight the challenges facing regenerative medicine. The briefing, titled “Organs on Demand: What’s Stopping Us from Made-to-Order Tissues and Organs,” brought together leaders in the field of regenerative medicine who are working to take this technology to the next level.

The purpose of the briefing, which took place April 10 at the Rayburn House Office Building, was to educate members of Congress and congressional staff on the opportunities that advances in this field have created for the future of modern healthcare, as well as some of the challenges preventing these opportunities from becoming a reality. Cosponsors of the briefing included the United Engineering Foundation, AIChE, AIME, ASCE and IEEE-USA.


David Vasko, director of advanced technology at Rockwell Automation, addressed some of the major obstacles related to the commercialization of regenerative medicine at the briefing.


Dean Kamen, executive director of the Advanced Regenerative Manufacturing Institute (ARMI) kicked off the event by delivering the keynote address. He discussed the work ARMI is undertaking, with a particular emphasis on ARMI’s new tissue foundry. Currently, patients in need of an organ transplant are limited in their options. They must wait for a suitable donor to come from another patient, after which they will spend the rest of their lives taking a cocktail of immunosuppresants to ensure their new organs are not rejected. But in the future, what if it were possible to simply grow a new organ from the patient’s own cells? This is what lies at the heart of ARMI’s tissue foundry. Kamen explained that the goal of the foundry is to create a space where new organs can be manufactured from a patient’s own cells, thereby eliminating the need to take an organ from another patient, as well as the myriad of immunosuppressant drugs the patient is required to take.

Kamen also explained that the regenerative medicine field is new and continuously evolving. There are very few large players in this market, with the majority of the work being carried out by small, innovative companies. At the current time, the majority of the research in regenerative medicine is taking place on a small scale in laboratories. Looking to other manufacturing fields outside of healthcare, it is easier to identify major players that are pushing technology forward. But the field of regenerative medicine, while small with relatively few players, is moving the needle on technological innovation and healthcare at a rapid rate. In discussing the work of ARMI and how regenerative medicine fits into the framework of American additive manufacturing, he noted, “We’re small compared to them [other manufacturing industry players], but we’re big compared to nothing.”


Jon Rowley, chief product officer at RoosterBio Inc., noted that the cost of tissue engineering must decrease in order for it to become commercially viable.

Following Kamen’s address, David Vasko, director of advanced technology at Rockwell Automation, spoke to the audience about some of the major obstacles standing in the way of creating tissue foundries and bringing regenerative medicine to the commercial market. Currently, these technologies take place on a small scale in a laboratory. This is expensive and hard to scale up due to the current regulatory climate and amount of time the technology takes. Introducing automation into the mix could have a significant impact on how regenerative medicine would look in the future, he said.

Jon Rowley, chief product officer of RoosterBio Inc., built on the premises Vasko discussed. Rowley explained that cells are the foundation of regenerative medicine. One of the biggest factors preventing regenerative medicine from large-scale commercialization, however, is the cost of cells. Currently the technology associated with regenerative medicine is very expensive. It can take millions to billions of cells to construct a new piece of tissue. Rowley noted that for tissue engineering to become commercially viable, the cost of the raw materials must decrease and consequently “as costs get reduced, sustainable businesses become a reality.”


Claudia Zylberberg, chief executive officer of Akron Biotech, spoke about the cell therapy process and state funding of regenerative medicine during her presentation at the briefing.

Rounding out the panel was Dr. Claudia Zylberberg, chief executive officer of Akron Biotech. Zylberberg broke down for the audience how cell therapies work, starting with blood collection and processing, all the way to end stage treatment. She also provided the same explanations for tissue engineering, building off of Rowley’s discussion in which he showed how cells and cell therapies are the foundation of tissue engineering. In addition, Zylberberg highlighted specific organizations dedicated to regenerative medicine at a state level. Through Zylberberg’s presentation, the state-by-state disparities in funding was made starkly clear. California and Texas are the leaders in state funding for regenerative medicine, both providing $3 billion a year to their organizations.

Zylberberg also provided a macro-level view of funding for regenerative medicine, pointing out that in 2018, nearly 1,000 companies were active in the regenerative medicine space, 50 percent of which were American. These companies raised $13.3 billion, a 73 percent increase form 2017. By 2024, the regenerative medicine market is expected to reach $40 billion.